ClinicalTrials.gg
CompletedNCT01290315Updated Feb 8, 2018Results posted

Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women

A Phase 2 interventional study of Ferric Carboxymaltose (FCM) and Iron Sucrose / Iron Dextran in Iron Deficiency Anemia, sponsored by American Regent, Inc.. Completed at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2018-02-08.

Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Aug 2009, registered Nov 2010).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency — 7 open to participants now, 7 under way, none of them phase 3. ferric carboxymaltose · Anemia, Iron-Deficiency.

Enrollment
38th of 57
49 · median 100
Started
2009
with 5 others
Phase 2
8 of 57
none open now
Registered
13th of 57
by date
Lead sponsor
11 of 57
American Regent, Inc.

Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, this one is the 38th largest by enrollment, is one of 6 that started in 2009, is one of 8 in phase 2, and was the 13th registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

7 of the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

The purpose of this study is to compare safety and the oxidative stress potential of two doses of an investigational IV iron, ferric carboxymaltose (FCM), compared to an equal single dose of IV iron sucrose or IV iron dextran in the treatment of Iron Deficiency Anemia (IDA) in female subjects.

Read the detailed description

This was a Phase 2a, open-label, multicenter, randomized study that compared the safety and oxidative stress potential of FCM vs. IV iron sucrose or IV iron dextran in female subjects with IDA. Subjects with a diagnosis of IDA who required iron supplementation met all inclusion and no exclusion criteria, and had given informed consent were randomized. The duration of the study for each subject was a maximum of 6 weeks.

Eligible subjects were randomized in a 1:1 ratio to FCM (Group A) or IV iron sucrose or IV iron dextran (Group B).

Group A subjects received a single undiluted dose of iron as FCM by a slow IV injection on Day 0. Cohort I received 500 mg and Cohort II received 750 mg. Group B subjects received a single dose of iron as IV iron sucrose or as IC iron dextran on Day 0. Cohort I receive 500 mg iron sucrose and Cohort II received 750 mg iron dextran. Iron dextran administration was preceded by a 25 mg test dose 1 hour prior to infusion.

All subjects had laboratory assessments at Baseline, 2 hours post-infusion, 24 hours post-infusion, Day 7 (drawn at the same time of day [within 4 hours] as the 24-hour visit), and Day 30 (drawn at the same time of day [within 4 hours] as the the 24-hour visit). On Days 7 and 30, the safety evalutation for all subjects included treatment-emergent adverse event reporting, concomitant medication review, physical examination including vital signs, and laboratory assessments. Any subject who withdrew from the study received a follow-up phone call 30 days after they received study drug.

03

Conditions studied

  • Iron Deficiency Anemia
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female subjects 18-50 years of age and able to give .
  • If post-partum, at least 10 days post delivery at Day 0.
  • Screening Visit local laboratory \< or = to 10 g/dL or \< or = to 12 g/dL with symptoms (dizziness and/or fatigue).
  • Screening Visit ferritin \< or = to 100 ng/mL or \< or = to 300 when TSAT is \< or = to 30%.
  • Documented unsatisfactory response or intolerance to oral iron.

Exclusion criteria

Exclusion Criteria:

  • Previous participation in a ferric carboxymaltose (FCM) clinical trial.
  • Known reaction to any component of ferric carboxymaltose, Venofer, or Dexferrum.
  • History of drug allergy or any history of rheumatoid arthritis or other diseases.
  • Current anemia not attributed to iron deficiency.
  • During the 10 day period prior to screening has been treated with antibiotics.
  • During the 30 day period prior to screening or during the study period has or will be treated with erythropoiesis stimulating agents.
  • Active within 5 years. Basal or squamous cell skin cancer is not exclusionary.
  • During the 30 day period prior to screening or during the study period has or will require a surgical procedure that necessitates general anesthesia.
  • Current (acute or chronic) infection other than viral upper respiratory tract infection.
  • or ALT at screening greater than 1.5 times the .
  • Known positive with evidence of active hepatitis.
  • Known positive -1/HIV-2 antibodies (anti-HIV).
  • Patient has an active diagnosis of asthma and is currently using an anti- asthmatic therapy.
  • Received an drug within 30 days of screening.
  • Alcohol or drug abuse within the past 6 months.
  • Hemochromatosis or other iron storage disorders.
  • Systolic blood pressure > or = to 180 or \< 80 mmHg or diastolic blood pressure > or = to 100 or \< 40 mmHg at screening or Day 0.
  • Chronic kidney disease.
  • Chronic inflammatory condition including but not limited to Lupus and Rheumatoid Arthritis.
  • Pre-term delivery \< 32 weeks.
  • Emergent C-section delivery.
  • Significant cardiovascular disease, including but not limited to myocardial infarction or unstable angina within 6 months prior to study inclusion or current history of Class III or IV congestive heart failure.
  • Any other laboratory abnormality, medical condition or psychiatric disorder which in the opinion of the investigator puts the subject's disease management at risk or may result in the subject being unable to comply with study requirements.
  • Night shift workers.
  • Breastfeeding planned on or after Day 0.
  • Pregnant or sexually-active female subjects who are of and who don't use an acceptable form of .
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Ferric Carboxymaltose (FCM)

    Intravenous iron

    Drug: Ferric Carboxymaltose (FCM)

  • Active comparator
    Iron Sucrose / Iron Dextran

    Intravenous iron

    Drug: Iron Sucrose / Iron Dextran

Interventions

  • One 500 mg dose at 100 mg/minute (Cohort I) or 750 mg dose at 100 mg/minute (Cohort II)

    Also known as: Injectafer

  • DrugIron Sucrose / Iron Dextran

    Drug pages: Iron sucrose · Iron-Dextran Complex

    One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I), or a 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)

    Also known as: Venofer, Dexferrum

06

What researchers measure

Primary outcomes

  1. Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)

    Time frame: Change from Baseline to Day 30

  2. Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)

    Time frame: Change from baseline to 2 hours post end IV infusion

  3. Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)

    Time frame: Change from baseline to 24 hours post end IV infusion

  4. Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)

    Time frame: Change from baseline to Day 7 post end IV infusion

07

Results

Posted Feb 8, 2018

Participant flow

Hospitals and Medical Clinics. December 6, 2010 through October 13, 2012.

Participant flow — Overall Study
MilestoneFerric Carboxymaltose (FCM) Cohort IIron Sucrose Cohort IFerric Carboxymaltose (FCM) Cohort IIIron Dextran Cohort II
Started14121013
Completed119108
Not completed3305
Withdrew: Adverse event0003
Withdrew: Selection criteria/compliance2102
Withdrew: Lost to follow-up0100
Withdrew: Withdrawal by subject1100

Outcome measures

PrimaryChanges From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)
Time frame:
Change from Baseline to Day 30
Reported as:
Mean · mg
Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)
mgFerric Carboxymaltose (FCM) Cohort IIron Sucrose Cohort IFerric Carboxymaltose (FCM) Cohort IIIron Dextran Cohort II
Carbonyl-11.90 ± 52.55-1.06 ± 38.722-12.37 ± 32.91-11.14 ± 48.57
8-isoprostane141.46 ± 892.16-369.50 ± 957.068.83 ± 81.2032.28 ± 233.41
PrimaryChanges From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)
Time frame:
Change from baseline to 2 hours post end IV infusion
Reported as:
Mean · mg
Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)
mgFerric Carboxymaltose (FCM) Cohort IIron Sucrose Cohort IFerric Carboxymaltose (FCM) Cohort IIIron Dextran Cohort II
Carbonyl2.07 ± 38.216.05 ± 24.69-8.66 ± 43.15-5.98 ± 23.71
8-isoprostane151.59 ± 833.75-420.02 ± 803.52-2.64 ± 30.44-5.92 ± 216.66
PrimaryChanges From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)
Time frame:
Change from baseline to 24 hours post end IV infusion
Reported as:
Mean · mg
Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)
mgFerric Carboxymaltose (FCM) Cohort IIron Sucrose Cohort IFerric Carboxymaltose (FCM) Cohort IIIron Dextran Cohort II
Carbonyl8.63 ± 23.24-6.92 ± 21.498.94 ± 87.05-11.57 ± 40.30
8-isoprostane198.67 ± 864.29119.26 ± 575.29-23.96 ± 60.0138.02 ± 190.07
PrimaryChanges From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)
Time frame:
Change from baseline to Day 7 post end IV infusion
Reported as:
Mean · mg
Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)
mgFerric Carboxymaltose (FCM) Cohort IIron Sucrose Cohort IFerric Carboxymaltose (FCM) Cohort IIIron Dextran Cohort II
Carbonyl11.69 ± 36.43-24.03 ± 65.55-18.20 ± 45.92-12.10 ± 54.85
8-isoprostane263.52 ± 896.57-417.89 ± 1030.83-29.35 ± 56.88-58.04 ± 159.58

Adverse events

Collected over 1 year and 10 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ferric Carboxymaltose (FCM)—0/24 (0%)6/24 (25%)
Iron Sucrose or Iron Dextran—2/25 (8%)10/25 (40%)
Most frequent serious events
Most frequent serious events
EventFerric Carboxymaltose (FCM)Iron Sucrose or Iron Dextran
Anaphylactic ReactionImmune system disorders0/242/25
Most frequent other events
Most frequent other events
EventFerric Carboxymaltose (FCM)Iron Sucrose or Iron Dextran
HypersensitivityImmune system disorders2/242/25
NauseaGastrointestinal disorders1/242/25
Anaphylactic reactionImmune system disorders0/242/25
RashSkin and subcutaneous tissue disorders0/242/25
Injection site bruisingGeneral disorders1/240/25
HypophosphataemiaMetabolism and nutrition disorders1/240/25
DizzinessNervous system disorders1/240/25
VomitingGastrointestinal disorders0/241/25
UrticariaSkin and subcutaneous tissue disorders0/241/25

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ferric Carboxymaltose (FCM) Cohort IIron Sucrose Cohort IFerric Carboxymaltose (FCM) Cohort IIIron Dextran Cohort IITotal
<=18 years00000
Between 18 and 65 years1412101349
>=65 years00000
Age, Continuous
Age, Continuous(years)Ferric Carboxymaltose (FCM) Cohort IIron Sucrose Cohort IFerric Carboxymaltose (FCM) Cohort IIIron Dextran Cohort IITotal
Mean32.1 ± 7.6629.6 ± 9.9339.2 ± 7.9739.2 ± 9.2134.8 ± 9.48
Sex: Female, Male
Sex: Female, Male(Participants)Ferric Carboxymaltose (FCM) Cohort IIron Sucrose Cohort IFerric Carboxymaltose (FCM) Cohort IIIron Dextran Cohort IITotal
Female1412101349
Male00000
Region of Enrollment
Region of Enrollment(participants)Ferric Carboxymaltose (FCM) Cohort IIron Sucrose Cohort IFerric Carboxymaltose (FCM) Cohort IIIron Dextran Cohort IITotal
United States1412101349
08

Study locations

1 site
  • Luitpold Pharmaceuticals, Inc.
    Norristown, Pennsylvania 19403, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2009 to primary completion in Mar 2013, 43 months.

Results were first posted in Feb 2018, 4 years 11 months after primary completion.

Of 16 phase 2 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 43 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2010
First posted
Feb 7, 2011
StartActual
Aug 2009
Primary completionActual
Mar 2013
CompletionActual
Aug 2013
Results first posted
Feb 8, 2018
Last update
Feb 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01290315
Responsible party
Sponsor
First posted
Feb 7, 2011
Start date
Aug 2009
Primary completion
Mar 2013
Completion
Aug 2013
Results posted
Feb 8, 2018
Last update
Feb 8, 2018

Study contacts

Linda M Mundy, MD, PhD
study director · American Regent, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion